Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma

Author:

Vale Claire L1,Tierney Jayne1,Bull Sarah J2,Symonds Paul R3

Affiliation:

1. MRC Clinical Trials Unit at UCL; Meta-analysis Group; Aviation House 125 Kingsway London UK WC2B 6SE

2. MRC Clinical Trials Unit; Meta-analysis Group; Aviation House 125 Kingsway London UK WC2B 6SE

3. Leicester Royal Infirmary; Department of Oncology; Leicester UK LE1 5WW

Publisher

Wiley

Subject

Pharmacology (medical)

Reference40 articles.

1. Aapro M Bolis G Chevallier B van der Burg MEL Poveda A de Oliveira C An EORTC-GCCG randomized phase II trial of doxorubicin versus dox-cisplatin (cDDP) in endometrial carcinoma Proceedings of the Annual Meeting of the American Society of Clinical Oncology 1994 275

2. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC-GCCG;Aapro;Annals of Oncology,2003

3. Multidrug treatment of advanced and recurrent endometrial carcinoma: a Gynecologic Oncology Group study;Cohen;Obstetrics and Gynecology,1984

4. Randomized phase II studies of cisplatin and a combination of cyclophosphamide-doxorubicin-cisplatin (CAP) in patients with progestin-refractory advanced endometrial carcinoma;Edmonson;Gynecologic Oncology,1987

5. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study;Fleming;Journal of Clinical Oncology,2004

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3